Observational study of XELOX in combination with bevacizumab for advanced or recurrent colorectal cancer - KPUMDS C-01 STUDY

Kyoto Prefectural University of Medicine0 个研究点目标入组 100 人开始时间: 2011年1月27日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1)Contraindication of bevacizumab oxaliplatin and capecitabine 2)Brain tumors or brain metastasis 3)Presence of cerebrovascular disease or symptoms less than 1 year prior to entry 4)Any surgical treatments oncluding skin-open biopsy, trauma surgery and other more intensive surgery within 4 weeks or aspiration biopsy within one week 5)Non-healing bone fracture 6)Uncontrolled peptic ulcer 7)Uncontrolled hypertension 8)the internal organ transplant 9)Interstitial pneumonitis, pulmonary fibrosis 10)Uncontrolled Infection 11)Renal failure to be treated, 1+ or higher proteinuria within 1 weeks prior to entry 12)History of adverse events related to DPD loss 13)Daily treatment wit high-dose aspirin (>=325/day) or non-steroidal anti-inflammatory medications 14)Pregnant women, nursing mothers, possibly pregnant women 15)Perforation of gastrointestinal tract less than 1 year prior to entry 16)Clinically significant (i.e. active) cardiovascular disease (>= Grade 2 according to the Common Toxicity Criteria of the National Cancer Institute, version 4), clinically important echocardiographic findigs, or past or current history (within the last 1 year) of myocardial infarction 17)Peripheral neuropathy of at least grade 1 18)Uncontrolled pleural and/or peritoneal effusion 19)Not appropriate for the study at the physician's assessment

发起方